<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01235351</url>
  </required_header>
  <id_info>
    <org_study_id>TIMI 56</org_study_id>
    <nct_id>NCT01235351</nct_id>
  </id_info>
  <brief_title>Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56</brief_title>
  <acronym>ELEVATE</acronym>
  <official_title>Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The TIMI Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The TIMI Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether higher as compared with lower maintenance doses of clopidogrel can
      adequately improve the degree of platelet inhibition in carriers of a reduced-function
      CYP2C19 allele.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clopidogrel blocks the P2Y12 ADP receptor on platelets and has been shown to reduce
      cardiovascular events in acute coronary syndrome (ACS) patients.However, inter-patient
      variability in the pharmacodynamic response to clopidogrel is well recognized, and patients
      with lesser degrees of platelet inhibition in response to clopidogrel have been shown to be
      at increased risk of cardiovascular events.

      One potential source of this variability is the metabolism of clopidogrel, which is a
      pro-drug requiring biotransformation to become an active antiplatelet compound. Cytochrome
      P-450 (CYP) enzymes play a role in the metabolism, and carriers of reduced-function genetic
      variants in CYP2C19 (~30% of the population) have lower active clopidogrel metabolite levels,
      diminished platelet inhibition, and higher rates of adverse cardiovascular events as compared
      with non-carriers in the setting of treatment with standard maintenance doses of clopidogrel.

      Aim: To determine whether higher as compared with lower maintenance doses of clopidogrel can
      adequately improve the degree of platelet inhibition in carriers of a reduced-function
      CYP2C19 allele.

      Hypotheses: The primary hypothesis is that subjects who carry a reduced-function CYP2C19
      allele will have improvement in platelet inhibition with higher maintenance doses of
      clopidogrel.The secondary hypothesis is that higher maintenance doses of clopidogrel in
      carriers of a reduced-function CYP2C19 allele will result in similar platelet inhibition as
      compared to a standard maintenance dose of clopidogrel in non-carriers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparisons of Vasodilator-stimulated Phosphoprotein (VASP) Phosphorylation Platelet Reactivity Index (PRI)</measure>
    <time_frame>Approximately every 2 weeks for 8 weeks</time_frame>
    <description>The outcome measurement was on-treatment PRI determined through flow cytometric assessment of phosphorylation status of VASP.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">335</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Clopidogrel - for CYP2C19*2 carriers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel for CYP2C19*2 gene carriers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel - for CYP2C19*2 non-carriers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel for CYP2C19*2 gene NON-carriers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 75 mg daily, 150 mg daily, 225 mg daily, and 300 mg daily based on genotype</description>
    <arm_group_label>Clopidogrel - for CYP2C19*2 carriers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 75 mg daily, 150 mg daily</description>
    <arm_group_label>Clopidogrel - for CYP2C19*2 non-carriers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (major):

          1. Between 18 and 75 years of age, inclusive.

          2. Have an indication for the use of clopidogrel defined as either spontaneous MI
             [hospitalized with final diagnosis of MI, excluding periprocedural or definite
             secondary MI (e.g., due to anemia or hypertensive emergency)] or PCI within the past 6
             months.

          3. Clinically stable and at least 4 weeks following the MI or PCI.

        Exclusion Criteria (major):

          1. Conditions that alter platelet function.

          2. Conditions that increase bleeding risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian T Ruff, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>TIMI Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TIMI Study Group</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Mega JL, Hochholzer W, Frelinger AL 3rd, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MS. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011 Nov 23;306(20):2221-8. doi: 10.1001/jama.2011.1703. Epub 2011 Nov 16.</citation>
    <PMID>22088980</PMID>
  </results_reference>
  <results_reference>
    <citation>Hochholzer W, Ruff CT, Mesa RA, Mattimore JF, Cyr JF, Lei L, Frelinger AL 3rd, Michelson AD, Berg DD, Angiolillo DJ, O'Donoghue ML, Sabatine MS, Mega JL. Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial. J Am Coll Cardiol. 2014 Jul 29;64(4):361-8. doi: 10.1016/j.jacc.2014.03.051.</citation>
    <PMID>25060370</PMID>
  </results_reference>
  <results_reference>
    <citation>Carreras ET, Hochholzer W, Frelinger AL 3rd, Nordio F, O'Donoghue ML, Wiviott SD, Angiolillo DJ, Michelson AD, Sabatine MS, Mega JL. Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial. Thromb Haemost. 2016 Jul 4;116(1):69-77. doi: 10.1160/TH15-12-0981. Epub 2016 Mar 24.</citation>
    <PMID>27009617</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2010</study_first_posted>
  <results_first_submitted>December 7, 2012</results_first_submitted>
  <results_first_submitted_qc>November 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 15, 2019</results_first_posted>
  <last_update_submitted>November 13, 2019</last_update_submitted>
  <last_update_submitted_qc>November 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Clopidogrel</keyword>
  <keyword>Genetics</keyword>
  <keyword>Platelet Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>335 patients from 32 sites were enrolled from October 2010 until September 2011.</recruitment_details>
      <pre_assignment_details>335 patients enrolled, 2 patients not genotyped 333 patient allocated to initial treatment with 75 mg and 150 mg clopidogrel</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CYP2C19*2 Non-Carrier</title>
          <description>Period 1: clopidogrel 75 mg and 150 mg for 14 days each Period 2: crossover to sequences of clopidogrel (75 mg first, then 150 mg, and 150 mg first, then 75 mg) for 14 days each.</description>
        </group>
        <group group_id="P2">
          <title>CYP2C19*2 Carrier</title>
          <description>Period 1: clopidogrel 75 mg and 150 mg for 14 days each Period 2: crossover to sequences of clopidogrel (225 mg first, then 300 mg, and 300 mg first, then 225 mg) for 14 days each.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Initial Treatment With 75 mg and 150 mg</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="247"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="237">4 allocated to initial treatment included in primary analysis</participants>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No follow-up sample</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment With Different Dose Sequences</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="233"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>75 mg First and Then 150 mg</title>
              <participants_list>
                <participants group_id="P1" count="116"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>150 mg First Then 75 mg</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>225 mg First Then 300 mg</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>300 mg First Then 225 mg</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="233"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CYP2C19*2 Non-Carriers</title>
        </group>
        <group group_id="B2">
          <title>CYP2C19*2 Carriers</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="247"/>
            <count group_id="B2" value="86"/>
            <count group_id="B3" value="333"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Mean Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.8" spread="9.9"/>
                    <measurement group_id="B2" value="58.6" spread="9.7"/>
                    <measurement group_id="B3" value="60.2" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparisons of Vasodilator-stimulated Phosphoprotein (VASP) Phosphorylation Platelet Reactivity Index (PRI)</title>
        <description>The outcome measurement was on-treatment PRI determined through flow cytometric assessment of phosphorylation status of VASP.</description>
        <time_frame>Approximately every 2 weeks for 8 weeks</time_frame>
        <population>Non-carriers did not receive clopidogrel 225 mg or 300 mg</population>
        <group_list>
          <group group_id="O1">
            <title>CYP2C19*2 Carriers</title>
            <description>Carrier of reduced function allele</description>
          </group>
          <group group_id="O2">
            <title>CYP2C19*2 Non-Carriers</title>
            <description>Not a carrier of reduced function allele</description>
          </group>
        </group_list>
        <measure>
          <title>Comparisons of Vasodilator-stimulated Phosphoprotein (VASP) Phosphorylation Platelet Reactivity Index (PRI)</title>
          <description>The outcome measurement was on-treatment PRI determined through flow cytometric assessment of phosphorylation status of VASP.</description>
          <population>Non-carriers did not receive clopidogrel 225 mg or 300 mg</population>
          <units>% of PRI</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clopidogrel 75 mg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="237"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" lower_limit="67.1" upper_limit="74.9"/>
                    <measurement group_id="O2" value="57.5" lower_limit="55.1" upper_limit="59.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clopidogrel 150 mg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.4" lower_limit="58.1" upper_limit="66.7"/>
                    <measurement group_id="O2" value="46.9" lower_limit="44.3" upper_limit="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clopidogrel 225 mg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.0" lower_limit="49.4" upper_limit="58.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clopidogrel 300 mg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.1" lower_limit="45.9" upper_limit="54.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CYP2C19*2 Carriers 75 mg</title>
          <description>Patient with a carrier of genotype given 75 mg of the drug</description>
        </group>
        <group group_id="E2">
          <title>CYP2C19*2 Carriers 150 mg</title>
          <description>Patient with a carrier of genotype given 150 mg of the drug</description>
        </group>
        <group group_id="E3">
          <title>CYP2C19*2 Carriers 225 mg</title>
          <description>Patient with a carrier of genotype given 225 mg of the drug</description>
        </group>
        <group group_id="E4">
          <title>CYP2C19*2 Carriers 300mg</title>
          <description>Patient with a carrier of genotype given 300 mg of the drug</description>
        </group>
        <group group_id="E5">
          <title>CYP2C19*2 Noncarriers 75 mg</title>
          <description>Patients who are non-carriers of the genotype given 75 mg of the drug</description>
        </group>
        <group group_id="E6">
          <title>CYP2C19*2 Noncarriers 150 mg</title>
          <description>Patients who are non-carriers of the genotype given 150 mg of the drug</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="233"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorder</sub_title>
                <description>1</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="233"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="233"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="16" subjects_affected="16" subjects_at_risk="233"/>
                <counts group_id="E6" events="11" subjects_affected="11" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jessica L. Mega, MD, MPH</name_or_title>
      <organization>TIMI Study Group</organization>
      <phone>6172780145</phone>
      <email>jmega@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

